Study of High Sensitive Troponin-I Level in End-stage Renal Disease Patients Receiving Hemodialysis

NCT ID: NCT02572466

Last Updated: 2016-01-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

207 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-02-28

Study Completion Date

2015-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study objective is to compare the high sensitive troponin-I level in end-stage renal disease patients received hemodialysis without acute cardiovascular event with healthy population. The investigators also determine the effect of hemodialysis on troponin I level as the secondary objective.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Human cardiac Troponin I (cTnI) is an composition of Troponin which is found in heart muscle cells. Molecular weight of cTnI is 23,875 Dalton consisting of 209 amino acids. \[1,2\] The cTnI have been used in the diagnosis of acute myocardial infarction(AMI). \[3,4,5\] According to ESC / ACCF / AHA / WHF, diagnosis of acute myocardial infarction rely on the data from clinical symptoms, Electrocardiogram (EKG) changes in the specific pattern, such as ST-segment elevation / depression, new left bundle branch block, and cardiac biomarker level rise over the 99th percentile upper reference limit, which makes the cTnI level was used to help in making diagnosis for patient coming with symptoms of angina in emergency room.

The current cTnI detecting test has developed more and more high sensitive(called "high-sensitive troponin-I; hsTnI") which can detected in the range 10-50,000 pg / ml (ng / L) \[6\], and it can detected cTnI level even in normal people unlike cTnI, which only reported positive or negative or lower than the limit of detection. Due to ARCHITECT stat High sensitive Troponin-I (Abbott diagnostic) capabilities, hsTnI level can be detected in normal people up to 96 percent.\[7\] The reference range of hsTnI which has been researched by Apple FS, et al.(2012) studying the 19 types of cardiac troponin I and T measurement was established. The 99th percentile values for general healthy population without hypertension, diabetes, kidney disease and myocardial infarction, aged 18-64 years was 36 ng / L in men (N = 272), 15 ng / L in women (N = 252) \[7\].

However, research to find the reference of hsTnI in some groups , especially in patients with kidney disease is still limited and the diagnosis of acute myocardial infarction also use the 99th percentile as the reference source which was researched in healthy population\[7\] which makes it difficult to interpret. Sometimes doctors may concluded that patients with rising hsTnI because of kidney disease. According to the research in the next section, there are both support and against in this idea. Therefore, the researchers aim to study hsTnI in patients with end-stage renal disease received hemodialysis compare with normal population.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

End-stage Renal Disease

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

high-sensitive troponin-I End-stage renal disease hemodialysis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ESRD group

1. Aged 18 years or older.
2. was diagnosed as End-stage renal disease for more than one year.
3. Attend hemodialysis 3 times a week consistently for more than 6 months.
4. Hemodialysis with Kt/V \> 1.2
5. No urine output or is less than 500 ml per day.
6. No symptoms of myocardial infarction Or were hospitalized with the similar diagnosis during the two weeks.

Hemodialysis

Intervention Type OTHER

ESRD group received long-term hemodialysis

Control group

1. Aged 18 years or older.
2. without kidney disease (eGFR \> 60 ml/min/1.73m2)

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Hemodialysis

ESRD group received long-term hemodialysis

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Aged 18 years or more.
* was diagnosed as End-stage renal disease for more than one year.
* Attend hemodialysis 3 times a week consistently for more than 6 months.
* Hemodialysis with Kt/V \> 1.2
* No urine output or is less than 500 ml per day.
* No symptoms of myocardial infarction Or were hospitalized with the similar diagnosis during the two weeks.

Exclusion Criteria

* Could not complete hemodialysis, or Kt / V \<1.2
* Has symptoms of myocardial infarction while receiving dialysis
* Has the abnormal symptom (fever, chill, low BP) While receiving dialys
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Chulalongkorn University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Khajohn Tiranathanagul

Assistant Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Khajohn Tiranathanagul, MD

Role: PRINCIPAL_INVESTIGATOR

Chulalongkorn University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

King Chulalongkorn Memorial Hospital

Bangkok, Bangkok, Thailand

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Thailand

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

271/57

Identifier Type: -

Identifier Source: org_study_id